RNS Number : 2891R Diaceutics PLC 06 June 2024

Diaceutics - Capital Markets Event - Wednesday, 12 June 2024

Belfast and London, 6 June 2024- Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, will host a virtual Capital Markets Event for analysts and investors on Wednesday, 12 June 2024 at 1400-1600 BST (0900-1100 ET).

The event will include presentations from senior Diaceutics managers and partners. The purpose of the event will be to give analysts and investors a deeper insight into the DXRX platform, its functionality and hear from partners as to how they use the platform to find patients.

Those wishing to attend can register using the following link:

https://us02web.zoom.us/webinar/register/WN WNsaZ-s8SfauitOYaWjdLA

Enquiries:

Diaceutics PLC

Ryan Keeling, Chief Executive Officer

Nick Roberts, Chief Financial Officer <u>investorrelations@diaceutics.com</u>

Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600

Ben Maddison Nick Harland Kate Hanshaw

Alma Strategic Communications

Caroline Forde Kinvara Verdon Kieran Breheny Tel: +44(0)20 3405 0205

Tel: +44 (0)28 9040 6500

diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseq.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

FND

MSCUPUBWQUPCGAA